Estimated stroke-free survival of folic acid therapy for hypertensive adults: Projection based on the CSPPT
Hypertension Jan 12, 2020
Zhang T, Lin T, Wang Y, et al. - Given the treatment of hypertensive patients with enalapril plus folic acid vs enalapril alone has caused a significant risk reduction of first stroke in the CSPPT (China Stroke Primary Prevention Trial) but the lifetime stroke-free survival related to the treatment remains unknown, so, researchers estimated lifetime incremental stroke-free survival for enalapril-folic acid vs enalapril alone by utilizing data from 19,053 participants of the CSPPT. Findings revealed a modest gain in lifetime stroke-free survival in relation to enalapril plus folic acid treatment vs enalapril alone. Besides, a significant benefit in terms of stroke-free survival was noted in certain subgroups ie, younger, male patients, those with lower baseline folate concentrations, higher baseline systolic blood pressure, higher baseline total cholesterol and blood glucose, and with MTHFR (methylenetetrahydrofolate reductase) C677T CT or TT genotype.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries